A review of nanotechnological approaches for the prophylaxis of HIV/AIDS

被引:59
作者
Date, Abhijit A. [1 ]
Destache, Christopher J. [1 ]
机构
[1] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA
关键词
HIV; Nanotechnology; Polymeric nanoparticles; Dendrimers; Prophylaxis; Vaginal delivery; HUMAN-IMMUNODEFICIENCY-VIRUS; MEDIATED IMMUNE-RESPONSES; ANTI-HIV ACTIVITY; INACTIVATED HIV-1-CAPTURING NANOSPHERES; BIODEGRADABLE POLYMER NANOPARTICLES; TENOFOVIR DISOPROXIL FUMARATE; VACCINE DELIVERY-SYSTEMS; CORE-SHELL NANOPARTICLES; CELL-ASSOCIATED HIV-1; PEG CHAIN-LENGTH;
D O I
10.1016/j.biomaterials.2013.05.012
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Successful treatment and control of HIV/AIDS is one of the biggest challenges of 21st century. More than 33 million individuals are infected with HIV worldwide and more than 2 million new cases of HIV infection have been reported. The situation demands development of effective prevention strategies to control the pandemic of AIDS. Due to lack of availability of an effective HIV vaccine, antiretroviral drugs and nucleic acid therapeutics like siRNA have been explored for HIV prophylaxis. Clinical trials shave shown that antiretroviral drugs, tenofovir and emtricitabine can offer some degree of HIV prevention. However, complete prevention of HIV infection has not been achieved yet. Nanotechnology has brought a paradigm shift in the diagnosis, treatment and prevention of many diseases. The current review discusses potential of various nanocarriers such as dendrimers, polymeric nanoparticles, liposomes, lipid nanocarriers, drug nanocrystals, inorganic nanocarriers and nanofibers in improving efficacy of various modalities available for HIV prophylaxis. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6202 / 6228
页数:27
相关论文
共 273 条
[1]   Formulation, pharmacokinetics and pharmacodynamics of topical microbicides [J].
Adams, Jessica L. ;
Kashuba, Angela D. M. .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2012, 26 (04) :451-462
[2]  
Agrawal Lokesh, 2003, J Immune Based Ther Vaccines, V1, P5, DOI 10.1186/1476-8518-1-5
[3]   Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice [J].
Akagi, T ;
Kawamura, M ;
Ueno, M ;
Hiraishi, K ;
Adachi, M ;
Serizawa, T ;
Akashi, M ;
Baba, M .
JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (02) :163-172
[4]   Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission [J].
Akil, Ayman ;
Parniak, Michael A. ;
Dezzutti, Charlene S. ;
Moncla, Bernard J. ;
Cost, Marilyn R. ;
Li, Mingguang ;
Rohan, Lisa Cencia .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2011, 1 (03) :209-222
[5]  
Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
[6]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[7]   Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination [J].
Aline, Fleur ;
Brand, Denys ;
Pierre, Josette ;
Roingeard, Philippe ;
Severine, Munier ;
Verrier, Bernard ;
Dimier-Poisson, Isabelle .
VACCINE, 2009, 27 (38) :5284-5291
[8]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[9]   Formulation of Tenofovir-Loaded Functionalized Solid Lipid Nanoparticles Intended for HIV Prevention [J].
Alukda, Dima ;
Sturgis, Timothy ;
Youan, Bi-Botti C. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (08) :3345-3356
[10]  
Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]